Q1 21: performance beyond recovery
30/04/21 -"The company has reported its Q1 sales figures that came in even above Q1 19’s. This growth can be attributed to good dynamics across all segments, market share gains, and a sharp recovery in ..."
Pages
57
Language
English
Published on
30/04/21
You may also be interested by these reports :
07/10/26
We have slightly increased our target price even though marginally reducing our Q3 2026 EBITDA estimates, reflecting ongoing weakness in China and ...
14/09/26
Equity markets ended lower on the week ending September 11 as the renewed surge in energy prices revived inflation concerns and pushed bond yields ...
01/09/26
Dormakaba delivered a resilient FY25/26, with 3.0% organic growth, a record 16.1% adjusted EBITDA margin, and stronger H2 momentum. Management guides ...
20/08/26
Our DCF increases as we raise our assumptions following a solid 2Q26 that demonstrated resilience in a still-challenging environment. The group ...